Cook Biotech receives an Innovative Technology designation from Vizient for the Biodesign® Rectopexy Graft.
The Innovative Technology designation recognizes Vizient-contracted products that bring improvements to the healthcare industry.
WEST LAFAYETTE, Indiana – Cook Biotech announces that its Biodesign Rectopexy Graft has received an Innovative Technology designation from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country.
Cook Biotech exhibited the Biodesign Rectopexy Graft at the Vizient Innovative Technology Exchange on October 17, 2023, in Dallas, Texas.
The Biodesign Rectopexy Graft is the first biologic graft specifically indicated for rectal prolapse repair. This biologic xenograft, made from porcine small intestinal submucosa (SIS), is suitable for use in open, laparoscopic, or robotic procedures and does not require any special orientation, sidedness, or storage. Once hydrated, the graft is translucent, which provides clear visualization for suture positioning. It does not require AATB tissue tracking, and it is MRI-safe. Data indicates that use of the Biodesign Rectopexy Graft results in only 0.7% graft-related complications and a 4.8% recurrence rate.1 Moreover, patients who receive the graft report 100% complete or partial symptom resolution.2
“We are excited to receive this Innovative Technology designation from Vizient. Cook Biotech is keenly aware that certain colorectal conditions require products specifically engineered to help the patients who have those conditions,” said Umesh Patel, president of Cook Biotech. “Connecting with Vizient customers on this and future innovations is an important part of our mission to serve patients.”
“A product receives this designation when it has a unique quality that differentiates it from its competitors,” Kelly Flaharty, Vizient senior director of contract services. “Our customer council determined that the Biodesign Rectopexy Graft met this standard and recognizes its potential to improve quality outcomes.”
Vizient has a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers. It represents approximately $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
Cook Biotech, a Cook Group company, has been a leader in regenerative medicine for over 25 years. We develop transformative advanced tissue-repair products that improve patient outcomes worldwide. Our products are derived from naturally occurring extracellular matrices with wide-ranging indications including hernia, soft tissue defects, rectopexy, wound care, and fistula.
1Internal Cook Biotech Incorporated document: RP2023-00012. In a clinical study involving 146 patients, seven recurrences were reported, and one patient complained of coccygeal pain where the graft was sutured to the sacral ligament.
2Ogilvie JW, Stevenson ARL, Powar M. Case-matched series of a non-cross-linked biologic versus non-absorbable mesh in laparoscopic ventral rectopexy. Int J Colorectal Dis. 2014; 29(12):1477-1483.